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ABSTRACT 
The P19CL6 cell-line, a clone of the P19 mouse 
embryonal carcinoma cell-line, has been exten-
sively used as a model for cardiomyocytes as 
these cells can be differentiated into a cardio-
myocyte phenotype upon incubation with di-
methyl sulfoxide. Uniquely, these cells can be 
observed to “beat” when monitored by mi-
croscopy. We started investigating the response 
of P19CL6 cells to fatty acids, but highly vari-
able results lead us to investigate the phenotype 
of the P19CL6 cells in more depth. In this study 
we demonstrated that the P19CL6 cells are re-
sponsive to adrenaline, but loose the “beating” 
phenotype after 16 passages in culture. Analysis 
of specific mRNA transcripts indicated that the 
P19CL6 cells express both cardiac- and skeletal 
muscle-specific genes, while global analysis of 
microarray data showed clear differences be-
tween the P19CL6 cells and cardiac tissue of 
embryonic or adult origin. In conclusion, our 
observations suggest caution in the use of the 
P19CL6 cells as a model of cardiomyocytes 
unless rigorous validation for the intended 
analysis has been undertaken. 
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1. INTRODUCTION 
There is a requirement for the development of realistic 
cell culture models both for basic research and the de-
velopment of novel therapeutic agents. However, for 
several tissues, including heart, no individual cell line has 
been successfully validated for these purposes; such a 
failure is usually the result of the loss of one or more 
specific phenotypic features associated with the target  
tissue in the cell line. One approach to mitigate these 
issues has been the utilisation of chemically-stimulated 
differentiation of stem cells, with the hope that these cell 
lines will have a more realistic phenotype than cell lines 
derived from fully differentiated tissue. Pluripotent em-
bryonic carcinoma cells have been reported as successful 
in vitro models of cardiac differentiation; for example, the 
P19 mouse embryonal carcinoma cell-line has been re-
ported to differentiate into an embryonic cardiac-muscle 
phenotype in vitro [1] upon the addition of dimethyl 
sulfoxide (DMSO) [2-5]. Differentiated P19 cells have 
been reported to retain the ability to spontaneously con-
tract and shown to express transcripts in a temporal 
manner during culture, suggestive of a cardiac-muscle 
phenotype [5-7], and as such these cells have therefore 
been extensively used to study cardiac cell physiology 
[1,2,5,6,8], although with the caveat that these cells are 
embryonic instead. However, in addition to these cardiac- 
muscle-specific properties, P19 cells also display pluri-
potent properties and can be differentiated into cells dis-
playing either a skeletal muscle or neural phenotype [1, 
3-5]. There has thus been some concern about the ho-
mogeneity of DMSO-differentiated P19 cultures, with a 
heterogeneous cell population following differentiation 
significantly reducing the utility of these cells as a car-
diac-muscle-specific model: There has thus been much 
interest in identifying subclones of P19 cells that more 
robustly differentiate into cardiomyocytes. The P19CL6 
cell-line, a sub-clone of P19 embryonal cells, has been 
reported to efficiently differentiate into beating cardio-
myocytes upon exposure to DMSO under adherent cul-
ture conditions [9] and has been widely used as an in vitro 
model of cardiovascular cells [1,2,10-16]. 
It is clear that the P19CL6 cell line has potential as a 
model system for the study of cardiomyocyte develop-
ment and differentiation, and indeed they are currently 
used as such. However, full characterisation and valida-
tion is required before they can be used for this purpose 
with full confidence. A review of the literature, focusing 
on P19CL6 and P19 cell culture conditions, shows that 
two separate methods are commonly used, namely ad-
herent and non-adherent culture conditions [1,5,9,10,17]. 
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In addition, vitamins and hormones such as adrenaline 
have been shown to act as potent inducers of P19 cell 
differentiation into cardiomyocytes in addition to the 
aforementioned DMSO [1,5,7,9]. In this study we have 
characterized the P19CL6 cells in more detail under dif-
ferent culture conditions, focusing in particular on util-
ising microarray methodologies to compare the P19CL6 
transcriptome against native cardiac-muscle and skele-
tal-muscle transcriptomes. These investigations represent 
the first robust examination of both P19CL6 transcrip-
tome and cardiac phenotype, and demonstrate that the 
P19CL6 cell-line displays only a limited cardiomyocyte 
phenotype that is dependent on passage conditions. As 
such we would advise caution in the use of this cell line as 
a ‘complete’ in vitro model of cardiac-muscle cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Cell culture media and reagents were obtained from In-
vitrogen Corporation (Paisley, U.K.) and Sigma-Aldrich 
Company Ltd. (Poole, U.K.). Materials and kits for RNA 
extraction, cDNA synthesis and RT-PCR were supplied 
by Promega Corporation (Southampton, U.K.), Amer-
sham Biosciences (Chalfont St. Giles, U.K.) and Qiagen 
Ltd. (Crawley, U.K.). Corning Life Sciences (Schi-
phol-Rijk, Netherlands) supplied the ProntoPlus mi-
croarray kit. Ambion Ltd. (Huntingdon, U.K.) supplied 
mouse heart and embryonic total-RNA, whereas mouse 
skeletal muscle and embryonic heart total-RNA were 
purchased from Panomics Inc. (Redwood City, U.S.A.) 
and Zyagen (San Diego, U.S.A.), respectively. 
2.2. Cell culture 
P19CL6 cells were purchased at passage 9 from Riken 
Cell Bank (Ibaraki, Japan) in growing flask and cultured 
in medium containing -MEM (minimal essential media) 
supplemented with 10% FBS (foetal bovine serum) and 
1% penicillin-streptomycin (10,000 Units/ml and 10 
mg/ml, respectively) [9]. To differentiate P19CL6 cells 
into cardiomyocytes, cells were plated in 6-well culture 
plates (10 cm2) at a density of 2104 cells/cm2 in standard 
medium containing 1% DMSO [9]. Cells were cultured 
for 15 days at 37C and 5% CO2 with medium refreshed 
every second day. For culturing P19CL6 cells under 
non-adherent conditions, cells were stimulated to form 
aggregates by incubation in bacterial petri dishes (1106 
cells/dish; 78 cm2), containing a thin layer of 0.5% agar, 
for 4 days with standard media containing 1% DMSO, 
before transfer to regular cell culture flasks for the re-
mainder on the incubation period [5]. Cell aggregates 
were collected by centrifugation and replated into culture 
flasks for 15 days at 37C and 5% CO2 in the presence of 
1% DMSO. The H9C2 (2-1) cell-line, a murine cell-line 
that expresses a skeletal muscle phenotype, was obtained 
from the European Collection of Cell Cultures (ECACC; 
Salisbury, U.K.) and cultured under the same adherent 
conditions as the P19CL6 cells. 
2.3. Determination of mRNA Levels by  
Reverse Transcriptase Polymerase 
Chain Reaction (RT-PCR) and cDNA  
Microarrays 
Total RNA was isolated from cells with Trizol reagent, as 
per manufacturer's instructions (Invitrogen Corporation, 
Paisley, U.K.). Whole heart and skeletal muscle tissues 
(upper leg muscle) were dissected from 10 week old male 
CD1 wild-type mice (+/+), homogenised in Trizol reagent 
using an Ultra-Turrax T8 homogeniser, and total RNA 
isolated as per manufacturer’s instructions. Gene-specific 
forward and reverse primers used in the one-step RT-PCR 
or nested PCR reactions are shown in Table 1. In samples 
that did not show detectable cDNA levels after an initial 
RT-PCR amplification the PCR products were reampli-
fied by nested PCR [18]. PCR products were separated by 
electrophoresis on 2% agarose gels containing ethidium 
bromide, and the identity of PCR products verified by 
sequencing.  
Microarray experiments were designed as 
dual-hybridisation optimal interwoven loops 
(http://exgen.ma.umist.ac.uk) [19-21]. cDNA was synthe-
sised from purified total- RNA and labelled by a direct 
labelling method in the presence of Oligo dT, nucleo-
tide mixture, Cy3-/Cy5- dCTP dyes, and SuperScript-II 
Reverse Transcriptase, based on Human Genome Map-
ping Project protocols (http://www.hgmp.mrc.ac.uk/). 
Purified Cy3- and Cy5- labelled cDNA samples (40 pmol 
each) were mixed in pairs (total volume 40 µl), according 
to the experimental plan, and hybridised to microarrays 
by incubation in hybridization chambers for 20 hours at 
50C, before post-hybridization washing and drying. 
Microarray images were acquired using an Affymetrix 
428 scanner (Affymetrix, Santa Clara, USA) and ana-
lysed with BlueFuse (BlueGnome Ltd., Cambridge, 
U.K.), including quantification of pixel intensities of the 
spots and excluding background intensity and artefact 
areas on the arrays. The data was filtered by eliminating 
low quality array spots, as determined by BlueFuse’s spot 
uniformity and circularity measurements (spot uniformity 
and circularity >0.5 in at least 50% of the arrays), and 
normalised by intensity-dependent per spot and per chip 
(LOWESS) normalisation with GeneSpring-7 data 
analysis software (Agilent Technologies UK Ltd, Stock-
port, UK).  
After Lowess normalisation and filtering of microarray 
data linear modelling (LLAMA; Live Linear Analysis of  
MicroArray) was performed (http://exgen.ma.umist.ac.uk) 
to convert data from the loop experiment into a linear 
model and generate differential gene expression estimates 
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Figure 1. Determination of the effect of (a) passage number 
and (b) adrenaline on the beating characteristic in P19CL6 
cells cultured under adherent conditions. (a) P19CL6 cells 
(passage 12) were cultured with 0-20 M adrenaline and 
pulse rate was recorded on day 15 of incubation. Linear re-
gression analysis showed a correlation of pulse rate with 
adrenaline concentration (y = 1.1x + 21.8, R2 = 0.541, P < 
0.001) and one-way ANOVA confirmed a significant effect 
of adrenaline on pulse rate in P19CL6 cells (P < 0.001). Cells 
were cultured in three biological repeats and beating was 
recorded in at least six localized areas in the well. a, b, and c 
represent groups with a significant difference in average 
pulse rate. (b) P19CL6 cells from different passage numbers 
(12-16) were cultured in the presence of DMSO and pulse 
rate (beats/min) was recorded on day 15 of incubation. Linear 
regression analysis shows a significant effect of passage 
number on pulse rate (y = -2.58x + 63.3, R2 = 0.486, P < 
0.001) and two-way ANOVA confirmed significance differ-
ence between the different passage numbers of P19CL6 cells 
(P < 0.01). 
between contrast pairs, i.e. Cy3/Cy5 ratios [20,21,33]. The 
P19CL6 samples consisted of three biological repeats, with 
each sample analyzed on at least three microarray slides 
(technical repeats), and these were reduced to a single 
sample during the LLAMA analysis. The data reduction 
generated by the LLAMA analysis was further evaluated 
by PCA (principal component analysis) and PLS (partial 
least squares regression) (Simca-P+, Umetrics, New Jersey, 
U.S.A.). The PCA analysis generated correlations be-
tween the different samples. In order to simplify the in-
terpretation of the PLS analysis, the P19CL6 sample was 
compared to skeletal muscle, adult and embryonic heart 
samples, with the H9C2 (2-1) sample removed. The PLS 
analysis was used to produce a variable importance (VIP) 
list and all genes with a VIP > 1, i.e. having a significant 
impact on the difference between the P19CL6 and other 
samples, were further analysed with the DAVID software 
suite (http://david.abcc.ncifcrf.gov/home.jsp) for func-
tional annotation clustering according to their biological 
functions [24]. 
a, b, c
a, b
c
b a
3. RESULTS 
a, b
In a series of separate cultures of P19CL6 cells it was 
noted that the cultures did not consistently display a 
“beating” phenotype, a characteristic that has previously 
been used as evidence of the cardiomyocyte properties of 
this P19 sub-clone [9]. 
c
a
b, c
3.1. P19CL6 Cells Exhibit a            
Cardiac-Muscle-Like ‘Beating’     
Phenotype under Specified Culture 
Conditions 
A characteristic of the P19CL6 cells is that they display 
beating in localised nodes following differentiation in the 
presence of DMSO [9]. The cardio-stimulatory chemical 
adrenaline elicited a dose-dependent linear increase in the 
observed pulse rate with statistically significant increases 
observed between 0-20 M adrenaline (Figure 1a). 
However, observation of P19CL6 cells over time in cul-
ture (passages 12-22) demonstrated that beating was 
consistently only observed between passages 12-16, and 
quantification of this beating showed a significant inverse 
correlation of the pulse-rate with passage number (Figure 
1b). Microscopic analysis of DMSO-differentiated P19- 
CL6 cells demonstrated mono-nuclear cells with no evi-
dence of cell fusion; these characteristics were distinct 
from the morphological characteristics of skeletal muscle 
cells, as typified by the H9C2 (2-1) murine cell-line 
(Figure 2), and added further weight to the assertion that 
differentiated P19CL6 cells exhibit a cardiac-specific 
muscle phenotype [5,10,34]. The microscopic analysis 
and response to adrenaline provided an indication of a 
cardiac-type phenotype, although the loss of beating with 
passage number suggested that the phenotype may not be 
robust with regards to culture duration.  
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Figure 2. Microscopic examination of P19CL6 and H9C2(2-1) 
cells. Cells were cultured on coverslips under adherent condi-
tions in the presence of DMSO and collected on day 15 of 
incubation. Cells were fixed using paraformaldehyde and 
observed by light microscopy under 40× magnification. (a) 
P19CL6 cells; (b) H9C2(2-1) cells. 
 
3.2. The P19CL6 Cell-Line Expresses both  
Cardiac- and Skeletal Muscle-Specific  
Transcripts 
To further examine the reported cardiac properties of the 
P19CL6 cell-line, mRNA transcript levels of -MHC, - 
MHC, MyoD and myogenin were determined by RT- 
PCR followed by nested PCR. The expression of these 
gene products are characteristic of cardiac- (-MHC, 
-MHC) and skeletal muscle (MyoD, myogenin) tissues 
[35-38]. Figure 3a shows that P19CL6 cells expressed 
significant levels of -MHC, -MHC, MyoD and myo-
genin transcripts, inconsistent with a cardiac only phe-
notype: To examine if the unexpected expression of 
skeletal muscle markers in P19CL6 cells was caused by 
the culture conditions we also examined P19CL6 under 
non-adherent culturing conditions; under these conditions 
we once again observed both cardiac- and skeletal mus-
cle-specific markers (Figure 3b), suggestive of a mixed 
cardiac/skeletal-muscle transcriptome in P19CL6 cells 
regardless of culture conditons. The identity of the - 
MHC, -MHC, MyoD and myogenin transcripts was 
confirmed by sequencing of the nested PCR products 
(data not shown). The marker transcript specificity was 
confirmed using both the H9C2 (2-1) cell-line, which 
expresses a skeletal muscle phenotype, and only ex-
pressed MyoD and myogenin transcripts and mouse car-
diac tissue, which only expressed the aforementioned 
transcript markers of cardiac phenotype, -MHC and 
-MHC (Figure 3c). These data were thus consistent 
with P19CL6 cells exhibiting a mixed cardiac/skeletal 
muscle phenotype, and therefore a global transcriptome 
analysis was under-taken to examine this hypothesis, 
comparing P19CL6 cells with the H9C2 (2-1) cell-line 
and mouse cardiac and skeletal muscle tissue. 
3.3. Characterisation of the P19CL6 
Cell-Line by Microarray Analysis 
Transcriptomes from three independent P19CL6 cultures 
were compared by microarray analysis to the transcript- 
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Figure 3 Expression of -MHC, -MHC, MyoD and myo-
genin, as detected by nested-PCR, in (a) P19CL6 and 
H9C2(2-1) cells, cultured under adherent conditions, (b) 
P19CL6 cells cultured under non-adherent conditions, upon 
exposure to 1% DMSO, and (c) mouse heart tissue. Cells 
were cultured under adherent or non-adherent conditions for 
15 days in the presence of 1% DMSO, as described under 
Methods. Heart tissue was dissected from 10 weeks old CD1 
wild type (+/+) male mice. Total RNA was isolated and 
mRNA levels determined by RT-PCR followed nested-PCR. 
Theoretical sizes of PCR products are 275 bp or 413 bp 
(GAPDH), 302 bp (-MHC), 410 bp (-MHC), 392 bp 
(MyoD) and 337 bp (myogenin), as indicated by the arrows. 
For Figure 3c the theoretical sizes of PCR products were: 
556 bp (GAPDH); 491 bp (-MHC); 587 bp (-MHC); 513 
bp (MyoD); and 608 bp (Myogenin), as indicated by arrows. 
Data shown of one experiment that is representative of three 
separate biological experiments. 
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tomes of mouse cardiac and skeletal muscle tissue, H9C2 
(2-1) cells, and a reference sample, which was a mixture 
of cDNA from all the samples in equal proportions. An 
interwoven loop design and data reduction by linear 
modelling [21-23] was utilized to compare all samples to 
the reference sample (Figure 4). The transcriptomes of 
all samples were initially analysed by PCA and showed a 
low correlation between the P19CL6 cells and other 
samples (Table 2, Figure 5). Only the embryonic heart 
sample did not differ significantly from the P19CL6 cells 
(P>0.05), although even this comparison showed a very 
low correlation of 0.007 (Table 2). Subsequent PLS 
analysis, excluding the H9C2 (2-1) samples in order to 
simplify interpretation, showed that principal component 
1 (PC1) accounted for 52% of the total variance and 
clearly separated the P19CL6 sample from the heart and 
muscle tissue (Figure 5). The loading factors for PC1 
showing a variable importance (VIP) of >1.0 represent 
those transcripts driving the separation of P19CL6 cells 
from the other samples; these were put into a biological 
context by ascertaining Gene Ontology (GO) identifiers 
that were significantly over-represented in the identified 
transcript level changes, using the DAVID bioinformatics 
suite [24]. Such over-representation is often indicative of 
a significant biological effect in the pathway(s) associated 
with the GO identifiers. Several annotation clusters with 
an enrichment score of greater than 1.0, i.e. showing 
significant enrichment, were identified (502 separate 
genes) and the five main Biological Processes that were 
identified are shown in Table 3. A more detailed analysis 
of the genes identified within the “Regulation of cellular 
processes” cluster showed that 57% (total number 146 
separate gene products) of the identified mRNA levels 
were up-regulated in P19CL6 cells compared to embry-
onic heart tissue, whereas the remainder were down- 
regulated (data not shown). The latter tissue was the 
primary focus for comparison as P19-derived cardio-
myocytes are embryonic in nature and have previously 
been used as a model system for the embryonic heart 
[1,6,8]. However, in the original P19CL6 paper this 
cell-line was proposed to be a good model system for 
adult heart [9]. 
4. DISCUSSION 
The P19CL6 cell-line, a derivative of P19 embryonal 
carcinoma cells, is widely used as an in vitro model of 
cardiovascular cells [1,2,10,16], and has been shown to 
differentiate into a beating phenotype that is reminiscent 
of cardiomyocytes upon exposure to DMSO [9]. Data 
presented here confirm that differentiated P19CL6 cells 
do exhibit some markers of a cardiac phenotype in the 
P19CL6 cells: a beating phenotype that is positively 
responsive to adrenaline; expression of transcript markers 
of cardiac phenotype (-MHC, -MHC); microscopic 
3
1
2
Figure 4: Khodadadi et al 2009
 
2
4 1
3 
7
6
3
1
2
5
44
A
C
B
 
a b 
c
Figure 4. Representation of dual-hybridisation optimal in-
terwoven loop design for microarray experiments. Loop de-
signs showing three, four, and seven samples (nodes) that 
were compared in three different experiments. The samples 
analysed in each experiment were (a) P19CL6 cells, mouse 
embryonic heart and mouse adult heart tissue (b) P19CL6 
cells, H9C2 (2-1) cells, mouse adult heart and mouse skeletal 
muscle tissue (c) P19CL6 cells (two different biological 
samples), H9C2 (2-1) cells, mouse embryonic heart tissue, 
mouse adult heart tissue, mouse skeletal muscle tissue and a 
reference sample, the latter containing cDNA from all the 
samples. The samples at the start of the arrows were labelled 
with Cy3 and the target samples with Cy5. 
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Figure 5. Analysis of transcriptomic expression data (microar-
rays) by PLS analysis. Gene expression data from microarray 
analysis was reduced by linear regression, using the LLAMA 
algorithm [19-21]. The data was further analysed by PCA and 
subsequently PLS to demonstrate discrimination between the 
samples (R2X for principal components 1 and 2 is 0.52 and 0.33, 
respectively) and generate a list of variable importance that 
could be used in the DAVID analysis. 
 
analysis showing mono-nuclear cells with no evidence of 
cell fusion [1,5,8,25]. However, closer examination of 
these features raises some concerns, and is suggestive of 
an unstable, mixed, cardiac/skeletal muscle phenotype. 
We demonstrated that the pulse-rate for beating was 
negatively correlated with the passage number of the cells, 
with no beating observed after passage 16, suggesting  
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Table 1. Sequences of oligonucleotide primers used for PCR. 
Oligo name Sequences %GC TmC Application Productsize
GAPDH-F 
ATT CAA CGG 
CAC AGT CAA 
GGC 
52 59.8 
GAPDH-R 
CAC ATT GGG 
GGT AGG AAC 
AC 
55 59.4 
RT-PCR 556 bp
GAPDH-F 
AGC TTG TCA 
TCA ACG GGA 
AGC 
52 59.8  
GAPDH-R 
CTA AGC AGT 
TGG TGG TGC 
AG 
55 59.4  
nested PCR 275 bp
GAPDH-F 
GAC TCC ACT 
CAC GGC AAA 
TTC 
52 59.8 
GAPDH-R 
AGT CTT CTG 
GGT GGC AGT 
GAT 
52 59.8 
nested PCR 413 bp
-MHC-F 
ATG GAG CAG 
ACC ATC AAG 
GAC 
52 59.8 
-MHC-R 
TTG TGT ATT 
GGC CAC AGC 
GAG 
52 59.8 
RT-PCR 491 bp
-MHC-F 
AAG AGT GAG 
CGG CGC ATC 
AA 
55 59.4 
-MHC-R 
CTG CTG GAG 
AGG TTA TTC 
CTC 
52 59.8 
nested PCR 302 bp
-MHC-F 
CTT CAA CCA 
CCA CAT GTT 
CGT G 
50 60.3 
-MHC-R 
TCA CCC CTG 
GAG ACT TTG 
TCT 
52 59.8 
RT-PCR 587 bp
-MHC-F 
GAG GGC ATT 
GAG TGG ACA 
TTC 
52 59.8 
-MHC-R 
CTT TCT TTG 
CCT TGC CTT 
TGC C 
50 60.3 
nested PCR 412 bp
MyoD-F 
AGT GAA TGA 
GGC CTT CGA 
GAC 
52 59.8 
MyoD-R 
CTG GGT TCC 
CTG TTC TGT 
GT 
55 59.4 
RT-PCR 513 bp
MyoD-F 
TAC CCA AGG 
TGG AGA TCC 
TG 
55 59.4 
MyoD-R 
GTG GTG CAT 
CTG CCA AAA 
GC 
55 59.4 
nested PCR 392 bp
MyoG-F 
AGC TGT ATG 
AGA CAT CCC 
CCT 
52 59.8 
MyoG-R 
ACG ATG GAC 
GTA AGG GAG 
TG 
55 59.4 
RT-PCR 608 bp
MyoG-F 
ACC AGG AGC 
CCC ACT TCT 
AT 
55 59.4 
MyoG-R 
GCG CAG GAT 
CTC CAC TTT 
AG 
55 59.4 
nested PCR 337 bp
F and R indicate forward and reverse primers, respectively. Tm: an-
nealing temperature (C); bp: base pair. 
Table 2. Correlation matrix of mRNA expression levels in 
P19CL6 and H9C2 (2-1) cells, and skeletal muscle, adult heart 
and embryonic heart tissue samples, as analyzed by microarray 
analysis. 
Samples H9C2 (2-1) Skeletal muscle Adult heart
Embryonic 
heart 
P19CL6 -0.058* -0.154** -0.210** 0.007 
H9C2 (2-1) -- 0.031 0.175** -0.023 
Skeletal muscle -- -- 0.299** -0.024 
Adult heart -- -- -- 0.373**
Microarray data was reduced by linear analysis using LLAMA and the 
data analyzed by PCA, with the data fitted to 5 components (explaining 
100% of the cumulative variance).  *P<0.05; **P <0.001. 
 
that the P19CL6 cells are subject to phenotypic drift with 
time in culture, and hence may not represent a stable 
cardiomyocyte phenotype. In addition, while P19CL6 
cells expressed the aforementioned transcript markers of 
cardiac phenotype (-MHC, -MHC), they also ex- 
pressed transcript markers for a skeletal muscle pheno- 
type (MyoD and myogenin), again suggestive of a mixed 
cardiac/skeletal muscle phenotype. Whereas examination 
of single markers can give an indication of the potential 
phenotype for a cell-line they are not necessarily indica-
tive of a fully functioning biological system. For example, 
liver cell-lines such as HepG2 have been validated for use 
in drug screening as hosts for both reporter genes and 
marker transcripts [26,27]; however, in-depth analysis 
demonstrates that this validation is simplified, with 
HepG2 cells unable to support some genome-based 
transcriptional activation and for the transcriptome to be 
markedly affected by culture conditions [28,29]. There-
fore whereas low complexity measurements may be 
suitable for validation of cell-lines for use in individual 
assays, approaches such as transcriptome/proteome 
analysis are more appropriate to fully characterize cell- 
lines [30]; anchoring this data to known phenotypic 
markers then allows an accurate assessment of the ap-
propriateness of any cell-line to the in vivo system they 
are supposed to be modelling [31]. Transcriptome analy-
sis of P19CL6 cells demonstrated significant differences 
in the transcript profile between these cells and other 
samples, including importantly both embryonic and adult 
cardiac cells. Gene Ontology over-representation analysis 
suggests that these transcripts are linked to biological 
pathways associated with cellular metabolism, an inter-
esting observation since it is generally accepted that car-
diac muscle cells have specific metabolic processes that 
differentiate embryonic and adult cardiomyocytes, and 
also skeletal and cardiac muscle cells. 
In conclusion, we have both undertaken physiological 
and transcriptome analysis of P19CL6 cells, assessing 
their suitability as models of cardiomyocytes for in vitro 
experimentation. Our data suggests that whereas the 
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P19CL6 cell-line has some phenotypic similarities to 
cardiomyocytes (e.g. the ability to pulse) there exist sig-
nificant differences between these cells and the in vivo 
situation. Our observations clearly demonstrate that the 
P19CL6 cell line does not maintain a robust cardia- 
myocyte phenotype as shown by the loss of cell beating 
with time in culture. In addition, transcriptome analysis 
clearly shows that even freshly differentiated cells do not 
exhibit a clear cardiac or muscle transcript profile, further 
questioning the utility of P19CL6 as a model system for 
the study of cardiomyocyte physiology. 
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ABBREVIATIONS 
 
 
ANOVA: Analysis of variance;  
DMSO: Dimethyl sulphoxide;  
RT-PCR: Reverse transcriptase polymerase chain reaction;  
PCA: Principle components analysis;  
PLS: Partial least squares regression;  
LLAMA: Live Linear Analysis of MicroArray.
 
 
